Astral - Biogen Brain Contusion Study
Posted Date: Sep 20, 2019
- Investigator: Laura Ngwenya
- Specialties: Emergency Medicine, Neurology, Neurosurgery
- Type of Study: Drug
This is a Biogen-sponsored clinical trial involving 96-hr infusion of study drug or placebo for brain contusion. The study drug is IV Glybenclamide (BIIB093), which is an IV formulation of the oral sulfonylurea anti-diabetic drug, glyburide. Subjects meeting eligibility (including CT scan showing brain contusion) must be randomized within 6 hours of the time of injury, and will receive the 96-hour infusion while admitted to the hospital. Blood glucose will be measured regularly during this time to monitor for potential hypoglycemia. Other study assessments include blood draws, ECGs, and vital signs. Patients are followed acutely until day 7 or discharge from the hospital, and follow-ups will be conducted in person or by phone at day 30, 90, and 180.
Criteria:
Patients With Traumatic Head Injury Causing Brain Contusion, And Less Than 6 Hours From Time Of Injury
Keywords:
Traumatic Brain Injury, Tbi, Glyburide
For More Information:
Hilary Perez
(513)558-2577
perezhe@ucmail.uc.edu